CDK4 and ovarian cancer: Unexpectedly, we found that ZC-22 showed a stronger anti-tumor effect than the combination of CDK4/6i Abemaciclib and PARPi Olaparib in breast and ovarian cancer at the same concentration (Figure 2B and Figure 5).